Vaccines Europe (VE) concurs with the responses submitted by EFPIA, whilst raising implications and concerns regarding the proposed GPL revision for vaccines and the industry developing and manufacturing them. Although the vaccine industry is a relatively small part of the pharmaceutical industry, it is particularly important for the EU and its citizens as it delivers more value than any other innovative industry.
VEV
Vaccines Europe (VE)
Industry association · Belgium · EU Transparency Register 53073567234-18
8
positions filed
in the 665 files tracked
6
legislative files
of 665 tracked
7
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1518 trade and business associations on this site, they rank #522 by legislative files engaged, a count of participation, not a measure of influence.
1.4
declared lobbying FTE
self-declared
€500K+
declared costs / yr (floor)
0
EP accreditations
as declared to the register
2011
in the register since
Declares membership of
- Vaccines Europe operates as a specialised group within the European Federation of Pharmaceutical Industries and Assoc…
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Trade and business associations
- Registered as
- Vaccines Europe (VE)
- Head office
- Luxembourg, Luxembourg
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Vaccines in PolicySpeak: request access →
Work at Vaccines Europe (VE)? so we know who speaks for it.
Their record over time
Vaccines Europe (VE) filed 8 positions between 2 Feb 2021 and 22 Jul 2026, across 6 of the 665 legislative files tracked here, attaching a full position paper 7 times.
2021 · 4 filed2023 · 1 filed2024 · 1 filed2025 · 1 filed2026 · 1 filed
What they argued
Vaccines Europe (VE) believes that this evaluation is an opportunity to implement learnings from COVID-19 to ensure a future-proof and resilient healthcare system. The pandemic shows the importance of: EU crisis preparedness, a flexible regulatory environment, maintaining and enhancing innovative research and development, and an industrial capability and capacity in the EU.
Vaccines Europe (VE) concurs with the responses submitted by EFPIA on proposed Biotech Act, while raising implications specific for vaccines development and manufacturing. Sitting at intersection of public health, innovation, and industrial policy, vaccines are one of the most advanced and impactful applications of biotechnology.
Vaccines Europe (VE) strongly supports the EFPIA submission. Additionally in this response, VE would like to emphasize the specific needs for vaccine innovation in Europe. Innovation in prophylactic vaccines has never been more critical.
Vaccines Europe (VE) representing vaccine companies operating in Europe welcomes the EC proposal to expand the ECDC’s mandate. In light of increased pandemic risks, it is critical to strengthen the role of ECDC.
The COVID-19 pandemic revealed the need for improvement in Europe’s capacity to respond to public health emergencies. Vaccines Europe (VE), a trade association representing the major innovative research-based vaccine companies as well as small and medium sized enterprises operating in Europe welcomes the Commission’s proposal to complement and further develop the core tasks of the EMA, to enhance the Union's…
The Covid-19 pandemic represents an unprecedented experience for all of us and for the EU’s remit in responding to cross-border health threats. In this regard, Vaccines Europe believes that the proposals from the Commission to strengthen the resilience and preparedness of Europe against serious cross border health threats should build on the lessons learned from the COVID-19 pandemic and provide for a clear…
VE welcomes the opportunity to contribute to the evaluation of the Regulation 2022/2371. In our response, we focus on two points related to 1/Reporting on prevention preparedness and response planning and 2/Joint procurement of medical countermeasures.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Vaccines Europe (VE) next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 96.
Is this your organization?
Everything on this page comes from Vaccines Europe (VE)’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.